Transthyretin as a potential CSF biomarker for Alzheimer’s disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors

Background:  Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer’s disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia.

[1]  E. Matsubara,et al.  Transthyretin Accelerates Vascular Aβ Deposition in a Mouse Model of Alzheimer's Disease , 2009, Brain pathology.

[2]  Anders Wallin,et al.  Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. , 2009, Journal of Alzheimer's disease : JAD.

[3]  L. Träskman-bendz,et al.  Transthyretin in cerebrospinal fluid from suicide attempters. , 2008, Journal of affective disorders.

[4]  P. Lewczuk,et al.  Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. , 2008, Methods.

[5]  Pritam Das,et al.  Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity , 2008, Proceedings of the National Academy of Sciences.

[6]  U. Heinemann,et al.  Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. , 2008, Journal of Alzheimer's disease : JAD.

[7]  J. Mann,et al.  Low Cerebrospinal Fluid Transthyretin Levels in Depression: Correlations with Suicidal Ideation and Low Serotonin Function , 2006, Biological Psychiatry.

[8]  I. Torres-Aleman,et al.  Serum insulin-like growth factor I in brain function. , 2006, The Keio journal of medicine.

[9]  G. Bernardi,et al.  Differential post‐translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid , 2006, Proteomics.

[10]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[11]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[12]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[13]  Juan Manuel Maler,et al.  Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau , 2004, Neurobiology of Aging.

[14]  J. Palha,et al.  Transthyretin is involved in depression‐like behaviour and exploratory activity , 2004, Journal of neurochemistry.

[15]  P. Lewczuk,et al.  Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. , 2004, Neurobiology of aging.

[16]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[17]  C. Lyketsos,et al.  Diagnosis and Treatment of Depression in Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[18]  Kaj Blennow,et al.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.

[19]  Jeffrey A. Johnson,et al.  Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways , 2002, The Journal of Neuroscience.

[20]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.

[21]  Anthony F Jorm.  History of Depression as a Risk Factor for Dementia: An Updated Review , 2001, The Australian and New Zealand journal of psychiatry.

[22]  J. Gorman,et al.  Low levels of transthyretin in the CSF of depressed patients. , 1999, The American journal of psychiatry.

[23]  G. Siest,et al.  Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry , 1998, FEBS letters.

[24]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[25]  W. Strittmatter,et al.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Gorman,et al.  CSF transthyretin in patients with depression. , 1993, The American journal of psychiatry.

[27]  H. Riisøen.  Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease , 1988, Acta neurologica Scandinavica.

[28]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[29]  A. Grubb,et al.  Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. , 1979, Scandinavian journal of clinical and laboratory investigation.

[30]  M. Åsberg,et al.  A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE , 1978, Acta psychiatrica Scandinavica. Supplementum.

[31]  J. Heremans,et al.  Immunochemical quantitation of antigens by single radial immunodiffusion. , 1965, Immunochemistry.